HomeAI · summaries
Storia in 9 fonti
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The company focuses on mental health treatments using psychedelic-based compounds. AtaiBeckley is developing an intranasal formulation for treatment-resistant depression. Talks are ongoing, and a deal could be announced this week.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
- ·
benzinga.com
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
